Analyst Ratings for [IMGN] ImmunoGen, Inc.

12/1/23	Downgrades	Buy Neutral	X
IMGN ImmunoGen Guggenheim
$25 $31
11/20/23	Initiated	Neutral	X
IMGN ImmunoGen Goldman
$17
11/9/23	Initiated	Buy	X
IMGN ImmunoGen Deutsche Bank
$25
10/6/23	Initiated	Perform	X
IMGN ImmunoGen Oppenheimer
$16
5/3/23	Upgrades	Neutral Overweight	X
IMGN ImmunoGen Piper Sandler
$6 $16
11/21/22	Initiated	Buy	X
IMGN ImmunoGen Truist
$10
9/9/22	Initiated	Overweight	X
IMGN ImmunoGen Barclays
$8
3/21/22	Downgrades	Outperform Sec Perform	X
IMGN ImmunoGen RBC Capital Mkts
$9 $6
2/11/22	Initiated	Outperform	X
IMGN Immunogen BMO Capital Markets
$18
12/1/21	Upgrades	Hold Buy	X
IMGN Immunogen Jefferies
$7 $12
8/13/19	Reiterated	Buy	X
IMGN Immunogen H.C. Wainwright
$4 $5
5/15/19	Downgrades	Buy Neutral	X
IMGN Immunogen Guggenheim
5/6/19	Upgrades	Mkt Perform Outperform	X
IMGN Immunogen Cowen
5/6/19	Upgrades	Neutral Buy	X
IMGN Immunogen H.C. Wainwright
$7
3/19/19	Downgrades	Neutral Underweight	X
IMGN Immunogen JP Morgan
3/5/19	Upgrades	Underweight Eq-Weight	X
IMGN Immunogen Morgan Stanley
3/4/19	Downgrades	Buy Neutral	X
IMGN Immunogen H.C. Wainwright
$18 $3.50
3/4/19	Downgrades	Outperform Mkt Perform	X
IMGN Immunogen SVB Leerink
3/1/19	Downgrades	Overweight Neutral	X
IMGN Immunogen Piper Jaffray
$13 $2.50
9/7/18	Initiated	Overweight	X
IMGN Immunogen Piper Jaffray
2/8/18	Resumed	Outperform	X
IMGN Immunogen RBC Capital Mkts
$12
1/31/18	Initiated	Buy	X
IMGN Immunogen H.C. Wainwright
$18

IMGN ImmunoGen, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.